| Christine Elizabeth Noteboom, APRN | |
|
275 S Perkins Rd, Stillwater, OK 74074-3665 | |
| (405) 200-8022 | |
| Not Available |
| Full Name | Christine Elizabeth Noteboom |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 7 Years |
| Location | 275 S Perkins Rd, Stillwater, Oklahoma |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1225541576 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363L00000X | Nurse Practitioner | R0103169 (Oklahoma) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Tulsa Emergency Medical Center Inc | 3375442692 | 49 |
| Medical Resource Management Llc | 4082753918 | 67 |
News Archive
Bristol-Myers Squibb Company today announced results from a Phase II study in which treatment with an all-oral, dual direct-acting antiviral (DAA) regimen of daclatasvir, an investigational NS5A replication complex inhibitor, and asunaprevir, an investigational NS3 protease inhibitor, achieved undetectable viral load 24 weeks post-treatment (SVR24) in 77% (33/43) of difficult-to-treat genotype 1b hepatitis C (HCV) patients.
Patients with acute coronary syndrome undergoing coronary angiogram, a procedure used to assess blockages in the heart's arteries, had a significantly lower risk of major bleeding and death if their interventional cardiologist accessed the heart through an artery in the arm rather than the groin, according to research presented at the American College of Cardiology's 64th Annual Scientific Session.
Teva Pharmaceutical Industries Ltd. today announced that data from four late-stage studies examining QNASL (beclomethasone dipropionate [BDP]) HFA, a nasal aerosol corticosteroid in development for the treatment of seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR) symptoms, will be presented at the 2011 Annual Meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Boston, Mass., November 3-8, 2011.
Dyax Corp. announced today treatment of the first patient in a Phase 2 trial evaluating the efficacy and safety of ecallantide, a potent, selective, reversible inhibitor of plasma kallikrein, for acute treatment of angiotensin converting enzyme (ACE) inhibitor-induced angioedema.
The Georgia Department of Community Health board on Thursday approved a plan to charge commercial HMOs the same fee as managed care companies that operate the state's Medicaid program in an effort to make up for a 5% reduction in program funding, the Savannah Morning News reports.
› Verified 1 days ago
| Entity Name | Tulsa Emergency Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063479087 PECOS PAC ID: 3375442692 Enrollment ID: O20040106000606 |
News Archive
Bristol-Myers Squibb Company today announced results from a Phase II study in which treatment with an all-oral, dual direct-acting antiviral (DAA) regimen of daclatasvir, an investigational NS5A replication complex inhibitor, and asunaprevir, an investigational NS3 protease inhibitor, achieved undetectable viral load 24 weeks post-treatment (SVR24) in 77% (33/43) of difficult-to-treat genotype 1b hepatitis C (HCV) patients.
Patients with acute coronary syndrome undergoing coronary angiogram, a procedure used to assess blockages in the heart's arteries, had a significantly lower risk of major bleeding and death if their interventional cardiologist accessed the heart through an artery in the arm rather than the groin, according to research presented at the American College of Cardiology's 64th Annual Scientific Session.
Teva Pharmaceutical Industries Ltd. today announced that data from four late-stage studies examining QNASL (beclomethasone dipropionate [BDP]) HFA, a nasal aerosol corticosteroid in development for the treatment of seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR) symptoms, will be presented at the 2011 Annual Meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Boston, Mass., November 3-8, 2011.
Dyax Corp. announced today treatment of the first patient in a Phase 2 trial evaluating the efficacy and safety of ecallantide, a potent, selective, reversible inhibitor of plasma kallikrein, for acute treatment of angiotensin converting enzyme (ACE) inhibitor-induced angioedema.
The Georgia Department of Community Health board on Thursday approved a plan to charge commercial HMOs the same fee as managed care companies that operate the state's Medicaid program in an effort to make up for a 5% reduction in program funding, the Savannah Morning News reports.
› Verified 1 days ago
| Entity Name | Medical Resource Management Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104056365 PECOS PAC ID: 4082753918 Enrollment ID: O20100830000840 |
News Archive
Bristol-Myers Squibb Company today announced results from a Phase II study in which treatment with an all-oral, dual direct-acting antiviral (DAA) regimen of daclatasvir, an investigational NS5A replication complex inhibitor, and asunaprevir, an investigational NS3 protease inhibitor, achieved undetectable viral load 24 weeks post-treatment (SVR24) in 77% (33/43) of difficult-to-treat genotype 1b hepatitis C (HCV) patients.
Patients with acute coronary syndrome undergoing coronary angiogram, a procedure used to assess blockages in the heart's arteries, had a significantly lower risk of major bleeding and death if their interventional cardiologist accessed the heart through an artery in the arm rather than the groin, according to research presented at the American College of Cardiology's 64th Annual Scientific Session.
Teva Pharmaceutical Industries Ltd. today announced that data from four late-stage studies examining QNASL (beclomethasone dipropionate [BDP]) HFA, a nasal aerosol corticosteroid in development for the treatment of seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR) symptoms, will be presented at the 2011 Annual Meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Boston, Mass., November 3-8, 2011.
Dyax Corp. announced today treatment of the first patient in a Phase 2 trial evaluating the efficacy and safety of ecallantide, a potent, selective, reversible inhibitor of plasma kallikrein, for acute treatment of angiotensin converting enzyme (ACE) inhibitor-induced angioedema.
The Georgia Department of Community Health board on Thursday approved a plan to charge commercial HMOs the same fee as managed care companies that operate the state's Medicaid program in an effort to make up for a 5% reduction in program funding, the Savannah Morning News reports.
› Verified 1 days ago
| Entity Name | Your Health Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396385431 PECOS PAC ID: 3870922008 Enrollment ID: O20200408004584 |
News Archive
Bristol-Myers Squibb Company today announced results from a Phase II study in which treatment with an all-oral, dual direct-acting antiviral (DAA) regimen of daclatasvir, an investigational NS5A replication complex inhibitor, and asunaprevir, an investigational NS3 protease inhibitor, achieved undetectable viral load 24 weeks post-treatment (SVR24) in 77% (33/43) of difficult-to-treat genotype 1b hepatitis C (HCV) patients.
Patients with acute coronary syndrome undergoing coronary angiogram, a procedure used to assess blockages in the heart's arteries, had a significantly lower risk of major bleeding and death if their interventional cardiologist accessed the heart through an artery in the arm rather than the groin, according to research presented at the American College of Cardiology's 64th Annual Scientific Session.
Teva Pharmaceutical Industries Ltd. today announced that data from four late-stage studies examining QNASL (beclomethasone dipropionate [BDP]) HFA, a nasal aerosol corticosteroid in development for the treatment of seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR) symptoms, will be presented at the 2011 Annual Meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Boston, Mass., November 3-8, 2011.
Dyax Corp. announced today treatment of the first patient in a Phase 2 trial evaluating the efficacy and safety of ecallantide, a potent, selective, reversible inhibitor of plasma kallikrein, for acute treatment of angiotensin converting enzyme (ACE) inhibitor-induced angioedema.
The Georgia Department of Community Health board on Thursday approved a plan to charge commercial HMOs the same fee as managed care companies that operate the state's Medicaid program in an effort to make up for a 5% reduction in program funding, the Savannah Morning News reports.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Christine Elizabeth Noteboom, APRN 3100 Nw 69th St, Oklahoma City, OK 73116-3307 Ph: (405) 200-8022 | Christine Elizabeth Noteboom, APRN 275 S Perkins Rd, Stillwater, OK 74074-3665 Ph: (405) 200-8022 |
News Archive
Bristol-Myers Squibb Company today announced results from a Phase II study in which treatment with an all-oral, dual direct-acting antiviral (DAA) regimen of daclatasvir, an investigational NS5A replication complex inhibitor, and asunaprevir, an investigational NS3 protease inhibitor, achieved undetectable viral load 24 weeks post-treatment (SVR24) in 77% (33/43) of difficult-to-treat genotype 1b hepatitis C (HCV) patients.
Patients with acute coronary syndrome undergoing coronary angiogram, a procedure used to assess blockages in the heart's arteries, had a significantly lower risk of major bleeding and death if their interventional cardiologist accessed the heart through an artery in the arm rather than the groin, according to research presented at the American College of Cardiology's 64th Annual Scientific Session.
Teva Pharmaceutical Industries Ltd. today announced that data from four late-stage studies examining QNASL (beclomethasone dipropionate [BDP]) HFA, a nasal aerosol corticosteroid in development for the treatment of seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR) symptoms, will be presented at the 2011 Annual Meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Boston, Mass., November 3-8, 2011.
Dyax Corp. announced today treatment of the first patient in a Phase 2 trial evaluating the efficacy and safety of ecallantide, a potent, selective, reversible inhibitor of plasma kallikrein, for acute treatment of angiotensin converting enzyme (ACE) inhibitor-induced angioedema.
The Georgia Department of Community Health board on Thursday approved a plan to charge commercial HMOs the same fee as managed care companies that operate the state's Medicaid program in an effort to make up for a 5% reduction in program funding, the Savannah Morning News reports.
› Verified 1 days ago
Connie R Lowry, ARNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 1815 W 6th Ave, Stillwater, OK 74074 Phone: 405-743-7300 | |
Debra O'day, Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1323 W 6th Ave, Stillwater, OK 74074 Phone: 405-372-1480 | |
Toby Lea Miller, APRN-CNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 1603 W 9th Ave, Stillwater, OK 74074 Phone: 405-379-0002 Fax: 405-300-1090 | |
Jeremiah Bro, APRN-CNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1301 W 6th Ave Ste 207, Stillwater, OK 74074 Phone: 405-533-3010 | |
Mrs. Laura De Mauriac Shaw, ARNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 1411 W 7th St, Ste 102, Stillwater, OK 74074 Phone: 405-624-8222 Fax: 405-372-3769 | |
Shanna Lynn Douglass, APRN-CNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1301 W 6th Ave Ste 207, Stillwater, OK 74074 Phone: 405-533-3010 | |
Sean Anderson, AGACNP-BC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 605 S Orchard St, Stillwater, OK 74074 Phone: 405-780-6650 Fax: 405-844-0562 |